Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ABVD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: ABVD. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002509-21 Sponsor Protocol Number: FIL-Rouge Start Date*: 2017-07-17
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response...
    Medical condition: Advanced stage (IIB-IV) Hodgkin Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009431-30 Sponsor Protocol Number: FM-HD09-01 Start Date*: 2009-07-03
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN’S LYMPHOMA.
    Medical condition: LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN’S LYMPHOMA.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003191-36 Sponsor Protocol Number: FIL-DDABVD Start Date*: 2012-02-09
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Dose-dense ABVD as first line therapy in early stage unfavorable Hodgkin’s Lymphoma: a phase II, prospective, multi-center study
    Medical condition: HODGKIN LIMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000734-35 Sponsor Protocol Number: BRAPP2 Start Date*: 2014-08-06
    Sponsor Name:LYSARC
    Full Title: Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD
    Medical condition: Patients aged from 18 to 70 years with supradiaphragmatic Ann Arbor clinical stage I or II classical Hodgkin lymphoma CD30+, FDG-PET positive score 4 & 5 according to Deauville criteria after 2 cou...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002227-42 Sponsor Protocol Number: UCL/17/0192 Start Date*: 2019-02-14
    Sponsor Name:University College London
    Full Title: Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study
    Medical condition: Advanced classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002382-33 Sponsor Protocol Number: NBK132/1/2020 Start Date*: 2021-04-12
    Sponsor Name:Medical University of Gdansk
    Full Title: Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles- RAFTING
    Medical condition: Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and constitutional symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004474-24 Sponsor Protocol Number: Uni-Koeln-987 Start Date*: 2009-07-09
    Sponsor Name:University of Cologne
    Full Title: HD16 for early stages in Hodgkins Lymphoma
    Medical condition: Hodgkin´s Lymphoma early stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002012-46 Sponsor Protocol Number: BV-ABVD Start Date*: 2012-11-15
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin Lymphoma
    Medical condition: Previously untreated patients with classical Hodgkin Lymphoma according to the World Health Organisation (WHO) classification
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020205 Hodgins LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002684-14 Sponsor Protocol Number: IIL HD 0801 Start Date*: 2008-10-20
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 pos...
    Medical condition: HODGKIN LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020205 Hodgins LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013839-37 Sponsor Protocol Number: HD0803 Start Date*: 2010-03-30
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A phase II multi-centre study of MBVD in elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).
    Medical condition: elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025319 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006064-30 Sponsor Protocol Number: UCL/07/146 Start Date*: 2008-04-09
    Sponsor Name:University College London
    Full Title: A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma
    Medical condition: Medical condition under investigation is Hodgkin Lymphoma, which is a cancer of the lymphatic system. It is usually treated with either chemotherapy or radiotherapy or a combination of both.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) IE (Completed) SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005450-60 Sponsor Protocol Number: C25003 Start Date*: 2013-02-09
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
    Medical condition: Advanced Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005920-34 Sponsor Protocol Number: Uni-Koeln-1014 Start Date*: 2011-10-14
    Sponsor Name:University of Cologne
    Full Title: HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET
    Medical condition: Hodgkin Lymphoma intermediate stage
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002765-37 Sponsor Protocol Number: 20051 Start Date*: 2006-08-15
    Sponsor Name:Euopean Organisation of Research and Treatment of Cancer
    Full Title: The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's...
    Medical condition: Hodgkin’s lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DK (Completed) FR (Completed) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001123-53 Sponsor Protocol Number: MK-3475-667 Start Date*: 2019-06-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response...
    Medical condition: cHL in children and young adults
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002927-13 Sponsor Protocol Number: FIL_A-BEGEV Start Date*: 2022-03-22
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase I/II b (randomized controlled) study of atezolizumab combined to BEGEV regimen as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate to autologous ...
    Medical condition: Refractory/relapsed Hodgkin Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020233 Hodgkin's disease mixed cellularity recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005473-22 Sponsor Protocol Number: 20101-23101 Start Date*: 2013-09-26
    Sponsor Name:EORTC
    Full Title: Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.
    Medical condition: Advanced stage Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001558-10 Sponsor Protocol Number: EORTC 20012 Start Date*: 2004-09-06
    Sponsor Name:HOSPITAL DE LA SANTA CREU I SANT PAU
    Full Title: BEACOPP (4 ciclos escalado + 4 ciclos basal) vs ABDV (8 ciclos) en el linfoma de Hodgkin en estadios III-IV.
    Medical condition: Enfermedad de Hodgkin estadios III-IV.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007168-94 Sponsor Protocol Number: HD0607 Start Date*: 2008-06-20
    Sponsor Name:AZIENDA OSPEDALIERA "S. CROCE E CARLE"
    Full Title: PHASE II MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN PTS WITH HIGH-RISK HODGKIN LYMPHOMA, IDENTIFIED AS FDG-PET SCAN POSITIVE AFTER TWO CONVENTIONAL ABVD COURSES
    Medical condition: HD ADVANCED DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022844-19 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Dijon
    Full Title: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma
    Medical condition: Hodgkin Lymphoma not previously treated
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 26 06:26:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA